An Open-Label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Tamura, Tomohide [1 ]
Nishio, Makoto [2 ]
Yamamoto, Nobuyuki [3 ]
Ohe, Yuichiro [1 ]
Wolff, Katharina [4 ]
Tsujimoto, Mika [5 ]
Enatsu, Sotaro [4 ]
Nakagawa, Kazuhiko [6 ]
机构：
[1] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
[2] Canc Inst Hosp Jfcr, Thorac Med Oncol, Tokyo, Japan
[3] Wakayama Med Univ Hosp, Med Oncol, Wakayama, Japan
[4] Eli Lilly Japan, Med Sci, Kobe, Hyogo, Japan
[5] Eli Lilly Japan, Stat Sci, Kobe, Hyogo, Japan
[6] Kinki Univ, Fac Med, Med Oncol, Osaka, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
gemcitabine-cisplatin; necitumumab; squamous non-small cell lung cancer; trial in progress;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-080
引用
收藏
页码：S664 / S665
页数：2
相关论文
共 50 条
  • [41] A phase 2 study of LY3023414 and necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC)
    Johnson, M.
    Wacheck, V.
    Hussein, M.
    McCleod, M.
    Daniel, D.
    Waterhouse, D.
    Gil, M.
    Strickland, D.
    Bendell, J. C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [42] A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer
    E. Kontopodis
    A. Kotsakis
    N. Kentepozidis
    K. Syrigos
    N. Ziras
    M. Moutsos
    G. Filippa
    A. Mala
    L. Vamvakas
    D. Mavroudis
    V. Georgoulias
    S. Agelaki
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 949 - 956
  • [43] Phase 2, Randomized, Open-Label Study of Ramucirumab in Combination With First-Line Pemetrexed and Platinum Chemotherapy in Patients With Nonsquamous, Advanced/Metastatic Non-Small Cell Lung Cancer
    Doebele, Robert C.
    Spigel, David
    Tehfe, Mustapha
    Thomas, Sachdev
    Reck, Martin
    Verma, Sunil
    Eakle, Janice
    Bustin, Frederique
    Goldschmidt, Jerome, Jr.
    Cao, Dachuang
    Alexandris, Ekaterine
    Yurasov, Sergey
    Camidge, D. Ross
    Bonomi, Philip
    CANCER, 2015, 121 (06) : 883 - 892
  • [44] A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer
    Kontopodis, E.
    Kotsakis, A.
    Kentepozidis, N.
    Syrigos, K.
    Ziras, N.
    Moutsos, M.
    Filippa, G.
    Mala, A.
    Vamvakas, L.
    Mavroudis, D.
    Georgoulias, V.
    Agelaki, S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (05) : 949 - 956
  • [45] Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer
    Zatloukal, Petr
    Gervais, Radj
    Vansteenkiste, Johan
    Bosquee, Leon
    Sessa, Christiana
    Brain, Etienne
    Dansin, Eric
    Urban, Thierry
    Dohollou, Nadine
    Besenval, Michele
    Quoix, Elisabeth
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (08) : 894 - 901
  • [46] A phase II study with vinorelbine, gemcitabine and cisplatin in the treatment of patients with stage IIIb-IV non-small cell lung cancer (NSCLC)
    Ginopoulos, P
    Mastronikolis, NS
    Giannios, J
    Karana, A
    Siabi, V
    Karvelas, F
    Rathossis, S
    Apostolopoulos, N
    Mastorakou, A
    LUNG CANCER, 1999, 23 (01) : 31 - 37
  • [47] Randomized multicenter phase II study with docetaxel in combination with either cisplatin or oxaliplatin as first-line treatment in patients with advanced or metastatic non-small cell lung cancer
    Atmaca, A.
    Al-Batran, S.
    Guener, T.
    Pauligk, C.
    Koepke, A.
    Bernhard, H.
    Wenzel, T.
    Banat, A. G.
    Brueck, P.
    Caca, K.
    Prasnikar, N.
    Kullmann, F.
    Jaeger, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non-Small-Cell Lung Cancer
    Camidge, D. Ross
    Berge, Eamon M.
    Doebele, Robert C.
    Ballas, Marc S.
    Jahan, Thierry
    Haigentz, Missak, Jr.
    Hoffman, David
    Spicer, James
    West, Howard
    Lee, Pablo
    Yang, Ling
    Joshi, Adarsh
    Gao, Ling
    Yurasov, Sergey
    Mita, Alain
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (10) : 1532 - 1539
  • [49] Phase III open-label comparison of gemcitabine/oxaliplatin versus paclitaxel/carboplatin as first line therapy for advanced non-small cell lung cancer (NSCLC)
    Weissman, C. H.
    Reynolds, C. H.
    Neubauer, M. A.
    Steinberg, I.
    Asmar, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients
    Tredaniel, J.
    Becht, C.
    Bekradda, M.
    De Cremoux, H.
    Alexandre, J.
    Chomy, F.
    Szyldergemajn, S.
    Yataghene, Y.
    Culine, S.
    LUNG CANCER, 2009, 63 (02) : 259 - 263
12345